Why did GAAP earnings fall so sharply despite revenue growth?

The main driver was a $1.75 billion pre-tax IPR&D impairment on assets acquired from Immunomedics in 2020, worth $1.04 per share after tax. Higher acquired IPR&D expense, including a $320 million Livdelzi royalty buy-out charge, also weighed on results. These are largely non-cash or one-time items, which is why non-GAAP EPS, while also down, reflects underlying trends more clearly.

How significant is the Immunomedics impairment for the company's balance sheet?

It is material: nine-month IPR&D impairments total $4.18 billion, and intangible assets fell to $20.5 billion from $26.5 billion at year-end 2023. Investors should watch whether further impairments arise on other acquired assets, since these charges reduce book equity, which declined to $18.4 billion from $22.7 billion.

What drove the raised full-year guidance?

Strong topline growth, particularly Biktarvy, plus higher expected Veklury sales ($1.8 billion versus a prior $1.3 billion) and disciplined operating expenses. Management raised product sales, operating income and EPS guidance. The GAAP diluted EPS guidance range ($0.05–$0.25) remains very low, reflecting the large year-to-date impairments and acquired IPR&D charges.

What are the key near-term catalysts for investors?

The most notable are the expected FDA filing for twice-yearly lenacapavir for HIV prevention before year-end 2024, the potential launch of that product, continued Livdelzi launch uptake, and Phase 3 data from the Arcellx-partnered anito-cel program. Investors should also monitor competition for Yescarta, which declined 1% in the quarter, and Trodelvy's U.S. urothelial withdrawal.

Is the dividend and capital return program at risk given lower cash levels?

Not immediately. Free cash flow of $4.2 billion in the quarter comfortably covered the $983 million in dividends and $300 million in buybacks. The board declared a $0.77 quarterly dividend for Q4 2024, though future dividends remain subject to board approval. Cash balances were reduced largely by the one-time $3.9 billion CymaBay acquisition rather than by operating shortfalls.

GILD 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed November 6, 2024. Cited figures are marked; the original filing is the authoritative source.

Gilead Sciences reported third quarter 2024 results on November 6, 2024, with total revenue up 7% year-over-year to $7.5 billion^a and product sales excluding Veklury up 7% to $6.8 billion.

Growth was led by HIV, where Biktarvy sales rose 13% to $3.5 billion^b, and by Oncology (up 6%) and Liver Disease (up 4%). Management raised full-year 2024 guidance for product sales ($27.8–$28.1 billion, up from $27.1–$27.5 billion), non-GAAP diluted EPS ($4.25–$4.45, up from $3.60–$3.90), and Veklury sales ($1.8 billion, up from $1.3 billion). GAAP diluted EPS was $1.00, down from $1.73, primarily due to a $1.75 billion non-cash IPR&D impairment tied to assets acquired from Immunomedics in 2020, along with $505 million of acquired IPR&D expense that included a $320 million charge to buy out Livdelzi royalties.

Beneath the headline numbers, profitability and balance sheet metrics warrant attention. Non-GAAP diluted EPS declined 12% year-over-year to $2.02^c because of higher acquired IPR&D and tax expense. Cash, cash equivalents and marketable debt securities fell to $5.0 billion from $8.4 billion at year-end 2023, largely reflecting the $3.9 billion CymaBay acquisition, and intangible assets declined to $20.5 billion from $26.5 billion, partly from the impairment.

Free cash flow was strong at $4.2 billion^d in the quarter, and the company paid $983 million in dividends and repurchased $300 million of stock. On the pipeline side, Gilead reported PURPOSE 2 Phase 3 data for twice-yearly lenacapavir HIV prevention, with 99.9% of participants uninfected, and said it expects to file with the FDA before year-end.

The company also received FDA accelerated approval for Livdelzi in primary biliary cholangitis, and announced plans to voluntarily withdraw the U.S. accelerated approval of Trodelvy in urothelial cancer following the TROPiCS-04 trial. The quarterly dividend was declared at $0.77 per share.

02—Key points

Key Highlights

Total revenue rose 7% year-over-year to $7.5 billion, with product sales excluding Veklury up 7% to $6.8 billion.
Biktarvy sales grew 13% to $3.5 billion, and total HIV sales rose 9% to $5.1 billion, driven by demand and realized pricing.
Full-year 2024 guidance was raised: product sales to $27.8–$28.1 billion, Veklury to $1.8 billion, and non-GAAP diluted EPS to $4.25–$4.45.
GAAP diluted EPS fell to $1.00 from $1.73 due to a $1.75 billion non-cash IPR&D impairment related to 2020 Immunomedics assets; non-GAAP diluted EPS fell 12% to $2.02.
Cash and marketable securities declined to $5.0 billion from $8.4 at year-end 2023, mainly reflecting the $3.9 billion CymaBay acquisition.
Free cash flow was $4.2 billion in the quarter, and the company returned capital through $983 million in dividends and $300 million in buybacks.
Pipeline progress included positive PURPOSE 2 data for twice-yearly lenacapavir HIV prevention, with FDA filing expected before year-end 2024, and FDA accelerated approval of Livdelzi.

03—Questions

Frequently Asked Questions

Why did GAAP earnings fall so sharply despite revenue growth?
The main driver was a $1.75 billion pre-tax IPR&D impairment on assets acquired from Immunomedics in 2020, worth $1.04 per share after tax. Higher acquired IPR&D expense, including a $320 million Livdelzi royalty buy-out charge, also weighed on results. These are largely non-cash or one-time items, which is why non-GAAP EPS, while also down, reflects underlying trends more clearly.
How significant is the Immunomedics impairment for the company's balance sheet?
It is material: nine-month IPR&D impairments total $4.18 billion, and intangible assets fell to $20.5 billion from $26.5 billion at year-end 2023. Investors should watch whether further impairments arise on other acquired assets, since these charges reduce book equity, which declined to $18.4 billion from $22.7 billion.
What drove the raised full-year guidance?
Strong topline growth, particularly Biktarvy, plus higher expected Veklury sales ($1.8 billion versus a prior $1.3 billion) and disciplined operating expenses. Management raised product sales, operating income and EPS guidance. The GAAP diluted EPS guidance range ($0.05–$0.25) remains very low, reflecting the large year-to-date impairments and acquired IPR&D charges.
What are the key near-term catalysts for investors?
The most notable are the expected FDA filing for twice-yearly lenacapavir for HIV prevention before year-end 2024, the potential launch of that product, continued Livdelzi launch uptake, and Phase 3 data from the Arcellx-partnered anito-cel program. Investors should also monitor competition for Yescarta, which declined 1% in the quarter, and Trodelvy's U.S. urothelial withdrawal.
Is the dividend and capital return program at risk given lower cash levels?
Not immediately. Free cash flow of $4.2 billion in the quarter comfortably covered the $983 million in dividends and $300 million in buybacks. The board declared a $0.77 quarterly dividend for Q4 2024, though future dividends remain subject to board approval. Cash balances were reduced largely by the one-time $3.9 billion CymaBay acquisition rather than by operating shortfalls.

04—Continue

← View all 8-K filings